Incepta Pharmaceuticals Ltd.
Adalimumab Immunology & rheumatology
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
| Brand | Strength | Form |
|---|---|---|
| Advixa | 40 mg/0.8 ml | SC Injection |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form |
|---|---|---|
| Baricent | 2 mg, 4 mg tablets | — |
| Baricent | 2 mg | Tablet |
| Baricent | 4 mg | Tablet |
Bevacizumab Cancer (oncology)
Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form |
|---|---|---|
| Bevixa | 100 mg/4 mL and 400 mg/16 mL | — |
| Bevixa | 100 mg/4 ml | IV Infusion |
| Bevixa | 400 mg/16 ml | IV Infusion |
Canagliflozin Diabetes & metabolic
Originator: Invokana · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma
| Brand | Strength | Form |
|---|---|---|
| Glicana | 100 mg | — |
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form |
|---|---|---|
| Crizocent | 250 mg capsule | — |
| Crizocent | 250 mg | Capsule |
Dapagliflozin Diabetes & metabolic
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
| Brand | Strength | Form |
|---|---|---|
| Dapaglip | 5 mg, 10 mg | — |
| Dapaglip | 5 mg | Tablet |
| Dapaglip | 10 mg | Tablet |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form |
|---|---|---|
| Empatab | 10 mg, 25 mg | — |
| Empatab | 10 mg | Tablet |
| Empatab | 25 mg | Tablet |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form |
|---|---|---|
| Ibrucent | 140 mg capsule | — |
| Ibrucent | 140 mg | Capsule |
Insulin Aspart Diabetes & metabolic
Originator: NovoRapid · Novo Nordisk
| Brand | Strength | Form |
|---|---|---|
| Glyset Mix (insulin aspart) | 100 IU/mL | — |
| Glyset Mix | 100 IU/ml | SC Injection |
Insulin Glargine Diabetes & metabolic
Originator: Lantus · Sanofi
| Brand | Strength | Form |
|---|---|---|
| Vibrenta | 100 IU/ml | SC Injection |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form |
|---|---|---|
| Linatab | 5 mg tablet | — |
| Linatab | 5 mg | Tablet |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Olacent | 100 mg and 150 mg tablets | — |
| Olacent | 100 mg | Tablet |
| Olacent | 150 mg | Tablet |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Osicent | 80 mg tablet | — |
| Osicent (exported to India) | 80 mg tablet | — |
| Osicent | 80 mg | Tablet |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form |
|---|---|---|
| Palbocent | 125 mg capsule | — |
| Palbocent | 125 mg | Capsule |
Pioglitazone Diabetes & metabolic
Originator: Actos; Actoplus Met and Actoplus Met XR · Takeda Pharmaceutical Company (first US approval 1999)
| Brand | Strength | Form |
|---|---|---|
| Piodar | 15 mg | — |
Rituximab Cancer (oncology)
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
| Brand | Strength | Form |
|---|---|---|
| Relyto | 10 mg/mL, 100 mg and 500 mg vials | — |
| Relyto | 10 mg/ml | IV Infusion |
Sitagliptin Diabetes & metabolic
Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.
| Brand | Strength | Form |
|---|---|---|
| Sitagil | 25 mg, 50 mg and 100 mg tablets | — |
| Sitagil | 100 mg | Tablet |
| Sitagil | 25 mg | Tablet |
| Sitagil | 50 mg | Tablet |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form |
|---|---|---|
| Panovir | 400 mg + 100 mg tablet | — |
| Panovir | 400 mg+100 mg | Tablet |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form |
|---|---|---|
| Tofacent | 5 mg and 10 mg tablets, 1 mg/mL oral solution, 11 mg XR tablet | — |
| Tofacent | 1 mg/ml | Oral Solution |
| Tofacent | 10 mg | Tablet |
| Tofacent | 5 mg | Tablet |
| Tofacent XR | 11 mg | Tablet (Extended Release) |
Trastuzumab Cancer (oncology)
Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form |
|---|---|---|
| Tresoda | 420 mg/20 mL | — |
| Tresoda | 420 mg/20 ml | IV Infusion |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
